Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 tezepelumab in severe uncontrolled asthma (Japan)
jRCT2080223791Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tezepelumab with Placebo (2 arms). Started Jan 2018; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2080223791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223791.